<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075928</url>
  </required_header>
  <id_info>
    <org_study_id>7861</org_study_id>
    <nct_id>NCT05075928</nct_id>
  </id_info>
  <brief_title>Description of a Cohort of COVID Patients With a Circulating Anticoagulant</brief_title>
  <acronym>LA-COVID</acronym>
  <official_title>Description of a Cohort of COVID Patients With a Circulating Anticoagulant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection&#xD;
      called COVID19. A large proportion of patients, in particular in severe forms, present with&#xD;
      thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A&#xD;
      significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it&#xD;
      possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous&#xD;
      prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using&#xD;
      standard hemostasis The objective of this study is to describe the diagnosis of thrombotic&#xD;
      complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or&#xD;
      aPL and the associated clinical and biological elements that may have favored thrombosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>retrospective study of thrombotic complications in a cohort of COVID patients with a circulating anticoagulant</measure>
    <time_frame>Files analysed retrospectively from March 01, 2020 to May 31, 2019 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SARS-COV-2</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Major patient infected with Covid-19, with a documented infection, having presented a&#xD;
        documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patient (≥18 years old)&#xD;
&#xD;
          -  Patient taken care of in the SMO pole or the NHC surgical resuscitation service or&#xD;
             hospitalized or consultant to the HUS between 01/03/2020 and 31/05/2020&#xD;
&#xD;
          -  Patient infected with Covid-19, with a documented infection, having presented a&#xD;
             documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis&#xD;
             assessment&#xD;
&#xD;
          -  or Patient infected with Covid-19, with a documented infection, without documented&#xD;
             thrombosis (arterial or venous), with in the standard work-up an increase in TCA&#xD;
             revealing the presence of LA&#xD;
&#xD;
          -  Subject having given his agreement for the reuse of his data for the purposes of this&#xD;
             research&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject having expressed opposition to participating in the study&#xD;
&#xD;
          -  Subject under guardianship or guardianship&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anne-Sophie Korganow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Sophie Korganow, MD, PhD</last_name>
    <phone>33 3 69 55 05 21</phone>
    <email>Anne-sophie.Korganow@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie Korganow, MD, PhD</last_name>
      <phone>33 3 69 55 05 21</phone>
      <email>Anne-sophie.Korganow@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Anne-Sophie Korganow, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier VOLLMER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick DIEUDONNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lélia GRUNEBAUM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MEYER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-COV-2</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Antiphospholipid syndrome (APS)</keyword>
  <keyword>autoimmune disease</keyword>
  <keyword>antiphospholipid antibodies (aPL)</keyword>
  <keyword>thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

